Eli Lilly's latest drug, retatrutide, has demonstrated significant weight loss and pain relief in a Phase 3 trial. The study, which focused on adults with obesity and knee osteoarthritis, showed that patients who remained on the highest dose lost an average of 28.7% of their body weight over 68 weeks. When including all participants, the weight loss averaged 23.7%. The drug also reduced knee osteoarthritis pain by up to 62.6% on average, with more than one in eight patients experiencing complete pain relief by the end of the trial.

Eli Lilly is positioning retatrutide for individuals with severe obesity , as 84% of trial participants had a body mass index (BMI) over 35.

Despite its efficacy, the drug had a high discontinuation rate, with 18% of patients on the highest dose stopping t

See Full Page